



Diurnal Limited
Cardiff Medicentre
Heath Park
Cardiff CF14 4UJ
United Kingdom

Disclosure of Transfers of Value Methodological Note for Diurnal 2022

Diurnal methodology, 2022

Diurnal is a small predominantly research-based company with two licensed products. During 2022 Diurnal marketed medicines in the United Kingdom, Germany, Austria and Italy. During this period the Diurnal medicines were also marketed in other countries, for example the United States, Sweden, Denmark, Norway and Iceland by partner organisations who disclose transfers of value as separate entities.

In November 2022 Diurnal was acquired by an American Pharmaceutical company, Neurocrine Biosciences. As of 1st November 2022, Diurnal is a wholly owned subsidiary of Neurocrine Biosciences.

Diurnal has agreed to comply with the ABPI Code of Practice to document and publicly disclose payments or other transfers of value made directly or indirectly to HCPs, ORDMs and HCOs. This note describes Diurnal's method of disclosure of Transfer of Value (ToV) for 2022 in accordance with the requirements of the ABPI code. All payments made during 2022 to external sources were reviewed, relevant payments for disclosure under the ABPI 2021 Code of Practice were identified, according to categories described in the table below.

	Example activities	HCP	HCO
Research and Development: ToV for non-clinical studies, clinical trials, non-interventional studies	Site fees; safety monitoring meetings; investigator-initiated research	✓	✓
Grants: Funding provided to support a specific activity that provides educational benefit or enhances patient care.	Grants		✓
Donations: Funding provided for an unspecified purpose.	Donations		✓
Travel and accommodation relating to a congress or educational event: In support of HCP attendance at congress or educational event	Travel (incl. flights, taxi, train, parking) Accommodation	✓	✓
Registration fees: ToVs related to the registration of an HCP / HCO to attend a congress or educational event.	Registration fees	✓	✓

Sponsorship agreements:	Congress sponsorship, stand/ booth space, symposia		✓
ToVs made to either the HCO directly or to an event organizer or other third party appointed by the HCO to manage an educational or scientific event.			
Fees for Service: ToVs resulting from or related to a contract where the HCP / HCO provides services	Advisory board, speaker services, consultancy services	✓	✓
Related expenses to the fees for service contract: ToVs related to a fee for service contract	Travel Accommodation	✓	✓

From 1st January 2022 until 31st October 2022 all in-scope ToV's made worldwide by Diurnal are declared. Diurnal does not have the means/mechanism to disclose values outside the UK e.g. in Austria, Germany and Italy, owing to a lack of affiliates, hence these ToV's are declared in full here.

From 1st November until 31st December, following the acquisition of Diurnal by Neurocrine Inc, all payments made by Diurnal to recipients outside the United States are declared. Transfers of Value made by Neurocrine Inc. from 1st November until 31st December, to recipients within Europe are declared.

ToV's declared include the VAT applied at different levels in countries in which the payment was made. Amounts declared are in UK sterling calculated with the conversion rates at the time of payment except for R&D. Here payments were aggregated by currency and the amount in UK sterling was calculated using an average exchange rate for that currency in 2022. Where contracts extend beyond a single year, in-year payments only are declared. Individual consent has been sought for individual payments to healthcare professionals with no refusals. Diurnal had no collaborative working agreements in 2022.